论文部分内容阅读
目的分析恩替卡韦对拉米夫定治疗失效的慢性乙型肝炎患者的治疗效果和安全性。方法选取拉米夫定治疗失效的慢性乙型肝炎患者86例为研究对象,随机分为观察组和对照组,每组43组。对照组采用安慰剂治疗,观察组采用恩替卡韦治疗。观察2组治疗前和治疗后2、4、6个月乙肝病毒基因检出值,乙肝病毒基因检出转阴率及不良事件发生情况。结果治疗后2、4、6个月,观察组乙肝病毒基因检出值低于对照组(P<0.01);观察组乙肝病毒基因检出转阴率为72.09%(31/43),高于对照组的6.98%(3/43)(P<0.01);观察组不良反应发生率为4.65%,低于对照组的30.23%(P<0.01)。结论对拉米夫定治疗失效的慢性乙型肝炎患者应用恩替卡韦治疗能促进患者早日改善病症,减少不良反应发生率,是治疗有效且安全的药物。
Objective To analyze the efficacy and safety of entecavir in treatment of chronic hepatitis B patients with lamivudine failure. Methods Eighty-six patients with chronic hepatitis B who failed lamivudine treatment were selected as study subjects and randomly divided into observation group and control group, with 43 in each group. The control group was treated with placebo and the observation group was treated with entecavir. Two groups were observed before and after treatment 2, 4 and 6 months after the detection of hepatitis B virus gene, hepatitis B virus gene detection rate and negative incidence of adverse events. Results The detected value of hepatitis B virus gene in observation group was lower than that in control group at 2, 4 and 6 months after treatment (P <0.01). The negative rate of detection of hepatitis B virus gene in observation group was 72.09% (31/43) 6.98% (3/43) in the control group (P <0.01). The incidence of adverse reactions in the observation group was 4.65%, which was lower than that in the control group (30.23%, P <0.01). Conclusion The treatment of chronic hepatitis B patients lamivudine failure treatment with entecavir can promote patients to improve the disease as soon as possible to reduce the incidence of adverse reactions, is an effective and safe drug treatment.